Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023452 · ClinicalTrials.gov registry record · Phase 3
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
A Phase 3 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,053
- Enrollment target
NCT00023452 is a Phase 3 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 8,053 participants.
The verdict
NCT00023452, a Phase 3 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,053 participants
- Enrollment target
Study Summary
Open-label, multi-center, Phase III clinical trial to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month (270-dose)regimen of daily isoniazid (9INH) to prevent tuberculosis (TB) among high-risk tuberculin skin-test reactors, including children and HIV-infected persons, who require treatment of latent TB infection (LTBI).
Interventions
- DRUG RPT + INH once weekly for 3 months given by DOT
- DRUG Isoniazid (INH) daily for 9 months
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,053 participants |
| Start Date | 2001-06 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023452
The ClinicalTrials.gov registry entry for NCT00023452 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,053 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RPT + INH once weekly for 3 months given by DOT is the first listed.
NCT00023452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00023452 about?
NCT00023452 is a clinical study titled "Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection". Open-label, multi-center, Phase III clinical trial to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month (270-dose)regimen of daily isoniazid (9INH) to prevent tuberculosis (TB) among high-...
What is the current status of trial NCT00023452?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,053 participants. The study started on 2001-06. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00023452?
The interventions under investigation include: RPT + INH once weekly for 3 months given by DOT (DRUG), Isoniazid (INH) daily for 9 months (DRUG).
Who is sponsoring clinical trial NCT00023452?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.